Mission Wealth Management LP Buys Shares of 4,231 Natera, Inc. (NASDAQ:NTRA)

Mission Wealth Management LP purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 4,231 shares of the medical research company’s stock, valued at approximately $265,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. RiverPark Advisors LLC bought a new stake in Natera during the 4th quarter worth approximately $27,000. Oliver Lagore Vanvalin Investment Group increased its holdings in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in Natera in the third quarter valued at $44,000. CWM LLC raised its position in Natera by 41.8% during the 4th quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock worth $117,000 after purchasing an additional 550 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Natera during the 3rd quarter worth about $111,000. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Up 3.5 %

NASDAQ NTRA opened at $96.98 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82. The business has a 50 day moving average price of $90.56 and a 200-day moving average price of $69.29.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. On average, analysts predict that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NTRA shares. Canaccord Genuity Group increased their price target on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Raymond James downgraded shares of Natera from a “strong-buy” rating to an “outperform” rating and boosted their price target for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research report on Friday, April 5th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research report on Tuesday, January 30th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $93.97, for a total value of $175,348.02. Following the transaction, the chief financial officer now owns 67,542 shares in the company, valued at $6,346,921.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Herm Rosenman sold 93,901 shares of Natera stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $69.37, for a total value of $6,513,912.37. Following the sale, the director now owns 61,685 shares of the company’s stock, valued at approximately $4,279,088.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the sale, the chief financial officer now directly owns 67,542 shares of the company’s stock, valued at approximately $6,346,921.74. The disclosure for this sale can be found here. Insiders have sold 420,779 shares of company stock worth $34,667,871 in the last quarter. Insiders own 9.42% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.